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Introduction: Lung cancers are characterized by high incidence, prevalence and mortality. They may be associated
with numerous paraneoplastic syndromes. Mild leukocytosis is not rare. The case described here, however, is of a
female patient with adenocarcinoma of the lung who developed extreme leukocytosis at over 140,000 cells/μL.
Descriptions of such leukemic forms of lung cancer are few and far between in the literature. In our case, the
complete hematological diagnostic investigation, which included cytological, immunocytological, cytogenetic,
histological and molecular genetic tests of the bone marrow (mutation analyses of BCR-ABL and JAK2), was
accompanied for the first time by a molecular genetic workup of the primary tumor for epidermal growth factor
receptor and K-RAS gene mutations.
Case presentation: We present the medical case of a 51-year-old female Caucasian patient, who was diagnosed
with a poorly differentiated stage IV (International Union Against Cancer staging) adenocarcinoma of the lung.
While undergoing treatment, our patient developed extreme leukocytosis, for which, despite extensive diagnostic
tests, no infection-related or hematological cause could be identified. The tumor proved to be highly resistant to
treatment. Our patient died only five months after the initial diagnosis.
Conclusion: A leukemoid course can most likely be interpreted as the paraneoplastic production of hematopoietic
growth factors. Despite the absence of a verified primary hematological origin, this possibility should always be
investigated in all patients in a comparable situation.Introduction
Both in Europe and in the US, lung cancer is by far
the most common fatal cancer in both sexes [1,2].
The classic symptoms include coughing, dyspnea and
hemoptysis. Particularly in small cell but also in non-
small cell lung cancer, paraneoplastic syndromes are
observed that, in terms of their characteristics and clin-
ical relevance, should be classified very differently. The
production of hormones or hormone precursors could
result in endocrine paraneoplasia. Examples include the
tumor-related production of parathyroid hormone, adre-
nocorticotropic hormone, antidiuretic hormone, thyroid-
stimulating hormone, insulin, erythropoietin, calcitonin
and serotonin. These are distinct from antibody-
mediated paraneoplasia, which may result in unusual* Correspondence: H.Riesenberg@uke.de
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distribution, and reproduction in any mediumskin changes (for example, dermatomyositis) but also in
severe neurological disorders (for example, myasthenia,
Lambert-Eaton syndrome).
It is not unusual for both small cell and non-small cell
lung cancers to be associated with mild leukocytosis.
These should be distinguished from the leukemoid
courses of non-small cell lung cancer, especially large
cell carcinoma, occasionally described in the literature,
where the development of extreme leukocytosis at over
50,000 cells/μL has been observed.
In the following case description, the origin of the
leukemoid course is discussed in detail under both
infection-related and hematological aspects, and expla-
nations offered for the resistance to treatment. In
addition, molecular genetic investigations of the primary
tumor are presented for the first time.Case presentation
We report on a 51-year-old female Caucasian patient
with no significant previous illnesses. Our patient hadtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Primary lesion. Pulmonary tumor in the right hilar region
with a diameter of 2.3cm in close proximity to the upper lobe and
encircling the right main bronchus.
Table 1 Blood count and infection parameters








Leukocytes (cells/μL) 7900 21,200 39,000 146,200
Hemoglobin (g/dL) 15.3 12.8 12.2 8.7
Platelets (cells/μL) 249,000 337,000 372,000 266,000
Neutrophils (%) - - 92 85
Lymphocytes (%) - - 4 1
Monocytes (%) - - 3 2
Eosinophils (%) - - 0 0
Basophils (%) - - 1 1
Metamyelcytes (%) - - - 6
Myelocytes (%) - - - 5
C-reactive protein
(mg/L)
2.8 19.5 43.2 49.3
Procalcitonin - - - 0.4
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use at the time of her first presentation. The initial
symptom, which first led the patient to contact her pri-
mary care physician, was pain in the region of her left
hip. She did not complain of cough, dyspnea, fever or
night sweats. Her weight remained constant.
A computed tomography (CT) scan of her left hip
joint demonstrated extensive osteolysis in the acetabu-
lum with infiltration of the iliopsoas muscle. Moreover,
bone fracture of the joint socket was highly suspected.
Magnetic resonance tomography (MRT) of her pelvis
confirmed the pathological fracture. Skeletal scintigraphy
found no further evidence of osteolysis.
We performed a CT-guided biopsy of the large area of
osteolysis in her left acetabulum. The histological diag-
nosis was of a poorly differentiated adenocarcinoma.
Despite extensive immunohistological chemical analyses
(pan-keratin focally positive; cytokeratin 8/18 moderately
positive; cytokeratin 5/6 weakly positive; cytokeratin 7
moderately to strongly positive; melanoma cocktail,
thyroid transcription factor-1, mammaglobin, thyroglo-
bulin, cluster of differentiation (CD) 56 and CD 138
negative), it proved impossible to assign the primary
tumor to a particular organ.
Moderate leukocytosis at 21,200 cells/μL was diag-
nosed as early as this point, in the presence of mild
anemia and normal platelet concentration. No leukocyte
differentiation was performed at this time. A routine
blood count from one and a half years before, exam-
ined retrospectively for this analysis, was without patho-
logical findings.
A CT scan of her neck, chest and abdomen and a
MRT scan of her cranium were performed. These
demonstrated a pulmonary tumor in her right hilar
region with a diameter of 2.3cm, in close proximity to
the upper lobe and encircling her right main bronchus
(Figure 1). Enlarged lymph nodes up to 2.5cm in size
and infracarinal lymph nodes up to 2.0cm in size were
observed in her right hilar region. In addition, numerous
pleural, pericardial and diaphragm metastases were diag-
nosed. No pulmonary metastases were seen. Excess
tissue was shown in her right infraclavicular region.
Abdominally, a distension of her left adrenal of 2.0cm in
diameter was assessed as highly suspect for metastasis.
The cranial MRT findings were normal.
The leukocyte concentration in the mean time was
elevated at 39,000 cells/μL, with largely unremarkable
differentiation (see Table 1).
Bronchoscopy and transbronchial needle aspiration
from her main and upper lobe carina demonstrated a
moderately to poorly differentiated adenocarcinoma
of the lung, consistent with the primary tumor of
the known metastasis in her left acetabulum. In mole-
cular pathological follow-up investigations, based on themetastasis of the acetabulum, no mutation of the epider-
mal growth factor receptor gene could be identified (wild
type). The K-RAS gene exhibited a mutation, which
argues in principle against the use of tyrosine kinase
inhibitors of the gefitinib type.
The next step involved radiotherapy of the area of
osteolysis in her left hip joint, including the surrounding
soft tissue metastasis, of up to 40Gy with a single dose
of 2Gy. In addition, simultaneous radio- and chemother-
apy was started consisting of radiotherapy of the primary
tumor and of the mediastinum up to 55.8Gy with a sin-
gle dose of 1.8Gy plus cisplatin (20mg/m², days 1 to 4
Figure 3 Bone marrow cytology. Massively increased and left-
shifted granulopoiesis up to the myeloblasts with displaced
erythropoiesis and normal megakaryopoiesis, as can typically
develop on stimulation with granulocyte colony-stimulating factor
(myeloblasts 4%, promyelocytes 12%, myelocytes 15%,
metamyelocytes 7%, band cells 13%, segmented neutrophils 31%,
proerythroblasts 2%, erythroblasts 16%, lymphocytes 2%).
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29, 36 and 43) was started.
In the course of the therapy, our patient reported pro-
gressive pain in the region of her left flank, which was
attributable to a considerable increase in the size of the
adrenal metastasis to 5.9 × 4.4 × 7.5cm. A blood count at
this point showed leukocytosis at 146,200 cells/μL, with
largely normal differentiation and complete maturation
(Figure 2).
Inflammation parameters were, at most, mildly ele-
vated (C-reactive protein 49.3mg/L, procalcitonin. 0.4).
She had no fever, so we assumed not so much an inflam-
matory reaction or abscess formation but rather feared
a hematological secondary disorder. Her levels of liver
transaminases were normal (aspartate transaminase
17U/L, alanine transaminase 21U/L). A cytological bone
marrow examination showed a massively increased and
left-shifted granulopoiesis up to the myeloblasts with
displaced erythropoiesis and normal megakaryopoiesis,
as can typically develop under stimulation with granulo-
cyte colony-stimulating factor (G-CSF) (Figure 3). In a
fluorescence activated cell sorting analysis, granulocytic
maturation of cells with partial coexpression of CD56
was predominantly seen. No immature cells were
detected; in principle, these findings seemed consistent
with the presence of myeloproliferative neoplasia.
Cytogenetic investigation showed a normal female
chromosome set (46,XX). Molecular genetic analysis
by means of fluorescence in situ hybridization ruled out
t(9;22) translocation. As expected, polymerase chain
reaction also failed to demonstrate a BCR-ABL fusion
gene. Similarly, a V617F mutation in the JAK2 gene
could also not be demonstrated, which overall makes the
presence of a myeloproliferative neoplasia very unlikelyFigure 2 Peripheral blood smear. Extreme leukocytosis with
largely normal differentiation and complete maturation (neutrophils
85%, lymphocytes 1%, monocytes 2%, eosinophils 0%, basophils 1%,
metamyelocytes 6%, myelocytes 5%).although it does not rule it out. On histology, a bone
marrow biopsy also provided no evidence supporting
either a hematological neoplasia, in particular chronic
myelogenous leukemia. (CML), or the presence of
infiltration by tumor cells.
Although our patient continued to exhibit no classic
signs of inflammation, the differential diagnosis of abscess
formation in the soft tissue metastasis in the iliopsoas
muscle had to be followed up, given the absence of evi-
dence for a hematological secondary disorder. How-
ever, this could not be confirmed by means of CT-guided
biopsy. The biopsy specimen proved to be just as sterile
as the repeatedly taken blood and urine cultures.
At the same time, the empirically initiated antibiotic treat-
ment, first with ceftriaxone and subsequently with pipera-
cillin and sulbactam sodium and also metronidazole, failed
to affect either the leukocyte concentration or the C-reactive
protein and procalcitonin to a clinically relevant degree.
Upon completion of the simultaneous radio- and chemo-
therapy, the primary tumor exhibited a slight regression.
The adrenal metastasis, however, had increased in size dur-
ing the ongoing therapy to 8.0× 4.8cm. We therefore attrib-
uted the regression of the primary tumor first and foremost
to the radiotherapy and initiated systemic second-line ther-
apy with docetaxel (30mg/m², once a week) and peme-
trexed (500mg/m², repeated on day 22). As there was no
clinical response and our patient’s general condition dete-
riorated continuously, this therapy was discontinued after
just one cycle. A third-line therapy with gemcitabine
(1,000mg/m², once a week) failed to have an effect either
on the primary tumor or on the leukocyte concentration.
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therapy.
Discussion
Leukemoid courses of various tumor entities, especially
gastrointestinal, urogenital, head-neck and lung cancers,
have been described in the literature [3]. The develop-
ment can be affected by a variety of factors. On the one
hand, this may involve the presence of an infection or
abscess formation. Equally, leukocytosis may be induced
in the short term by the administration of high-dose cor-
ticosteroids. Another possible cause that needs to be
considered is an existing or secondary hematological
neoplasia, which develops following previous therapy
[4,5]. The cause most discussed in the literature, how-
ever, is paraneoplastic production of hematopoietic
growth factors. Asano et al. published the first report
of CSF-producing lung cancers, characterized by the
development of extreme neutrophilia. The neutrophilia
was transferred to nude mice by the transplantation of
tumor cells [6]. Likewise, several subsequent investiga-
tions demonstrated elevated serum concentrations of
the hematopoietic growth factors G-CSF, granulocyte-
monocyte (GM)-CSF and also interleukin-6 in patients
with lung cancer and extreme neutrophilia [7-9].
In an investigation published by Kasuga et al., out of
33 patients with tumor-associated leukocytosis (leuko-
cytes from 11,400 cells/μL to 190,000 cells/μL) and ele-
vated serum concentration of various hematopoietic
growth factors demonstrated by means of enzyme-linked
immunoassay, only one patient exhibited small cell lung
cancer. All the other patients exhibited non-small cell
lung cancers, with the highest incidence being that of
large cell carcinoma. In the case of the severe leukemoid
courses (leukocytes >50,000 cells/μL), patients with large
cell carcinoma also showed the highest incidence at
27.8%, whereas leukocyte concentrations above 50,000
cells/μL were demonstrated in just 0.8% of the identified
adenocarcinomas and in 3.3% of the squamous epithelial
carcinomas [10].
In a single case report on a patient with a leukemic
course of a lung cancer, differentiation from CML was
provided by a bone marrow biopsy; but no conclusions
were reached on the precise histology of the primary
tumor or with regard to molecular genetics [11].
As an example, we may refer here to the study by
Shalom et al., which reports two patients (a 61-year-old
woman with poorly differentiated large cell carcinoma
and a 43-year-old man with poorly differentiated squa-
mous epithelial carcinoma) in an extensively metasta-
sized situation at the initial diagnosis, who, during the
course of the illness, exhibited leukocyte concentrations
exceeding 150,000 cells/μL with the neutrophil granulo-
cyte fraction exceeding 90%. In both cases, neither theinfection-related parameters nor the polymerase chain
reaction for BCR-ABL proved conclusive for ruling
out CML. No further hematological investigations or
analysis of the primary tumor were performed. Both
patients failed to benefit at any time from their chemo-
therapy, and died only four and seven months after the
initial diagnosis [12].
In the case described here, extensive diagnostic tests
ruled out infection-related and primary hematological
causes for the leukocytosis. A paraneoplastic origin
seems likely. It is known that, to a high degree, epithelial
tumors can express various forms of the G-CSF receptor
and that cell proliferation may occur after ligand binding
[13]. Paraneoplastic production of growth factors by the
tumor itself would mean permanent stimulation of these
tumor cells and explain the high aggressiveness and the
uncontrollable progression. It is impossible to judge at
this time if potential G-CSF and GM-CSF-stimulated
signal transduction can be influenced by medication.
Conclusions
In rare cases, lung cancer can exhibit a leukemoid course.
Where there is autonomous production of hematopoietic
growth factors by the tumor cells themselves and concur-
rent, uncontrollable proliferation, the prognosis for such
lung cancers is very poor. To distinguish between this
paraneoplastic phenomenon and primary hematological or
therapy-related secondary neoplasia, extensive hematolog-
ical diagnostic tests should always be carried out.
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